KDOQI (Kidney Disease Outcomes Quality Initiative)


Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism
History of KDOQI

KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease


1. Collins AJ, Roberts TL, St Peter WL, Chen SC, Ebben J, Constantini E: United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis 39:784-795, 2002

2. Eknoyan G, Agodoa L: On improving outcomes and quality of dialysis care, and more. Am J Kidney Dis 39:889-891, 2002

3. KDOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39:S1-S246, 2002 (suppl 1)

4. Arnaud CD: Hyperparathyroidism and renal failure. Kidney Int 4:89-95, 1973

5. Bricker NS, Slatopolsky E, Reiss E, Avioli LV: Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 123:543-553, 1969

6. Coburn JW, Elangovan L, Goodman WG, Frazao JM: Calcium-sensing receptor and calcimimetic agents. Kidney Int Suppl 73:S52-S58, 1999

7. De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E: Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 326:969-974, 1992

8. Fukagawa M: Cell biology of parathyroid hyperplasia in uremia. Am J Med Sci 317:377-382, 1999

9. Llach F: Calcific uremic arteriolopathy (calciphylaxis): An evolving entity? Am J Kidney Dis 32:514-518, 1998

10. Llach F, Massry SG: On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61:601-606, 1985

11. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427-1432, 1998

12. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR: Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 78:357-364, 1973

13. Proudfoot D, Shanahan CM, Weissberg PL: Vascular calcification: New insights into an old problem. J Pathol 185:1-3, 1998

14. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure—An evolving disorder. Kidney Int 43:436-442, 1993

15. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984

16. Massry SG, Coburn JW, Popovtzer MM, Shinaberger JH, Maxwell MH, Kleeman CR: Secondary hyperparathyroidism in chronic renal failure. The clinical spectrum in uremia, during hemodialysis, and after renal transplantation. Arch Intern Med 124:431-441, 1969

17. Malluche HH, Faugere MC: Effects of 1,25(OH)2D3 administration on bone in patients with renal failure. Kidney Int Suppl 29:S48-S53, 1990

18. Malluche H, Faugere MC: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int 38:193-211, 1990

19. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310:358-363, 1995

20. Goodman WG, Coburn JW: The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 43:227-237, 1992

21. de Caestecker MP, Bottomley M, Telfer BA, Hutchinson IV, Vose BM, Ballardie FW: Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Kidney Int 44:1298-1308, 1993

22. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascular access morbidity in the United States. Kidney Int 43:1091-1096, 1993

23. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R: Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44:1071-1077, 1993

24. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A: Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 11:2430-2438, 1996

25. Quigg RJ, Brathwaite M, Gardner DF, Gretch DR, Ruddy S: Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis 25:798-800, 1995

26. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26:622-631, 1995

27. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000

28. Urena P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, Souberbielle JC, Segre GV, Drueke TB, De Vernejoul MC: Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 10:932-939, 1995

29. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701, 2002

30. Rumberger JA, Brundage BH, Rader DJ, Kondos G: Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc 74:243-252, 1999

31. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084-1093, 1999

32. Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M: Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 89:666-671, 2000

33. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26:836-844, 1995

34. Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73:516-524, 1991

35. DeVita MV, Rasenas LL, Bansal M, Gleim GW, Zabetakis PM, Gardenswartz MH, Michelis MF: Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore) 71:284-290, 1992

36. Huraib S, Souqqiyeh MZ, Aswad S, al-Swailem AR: Pattern of renal osteodystrophy in haemodialysis patients in Saudi Arabia. Nephrol Dial Transplant 8:603-608, 1993

37. Eastwood JB: Quantitative bone histology in 38 patients with advanced renal failure. J Clin Pathol 35:125-134, 1982

38. Hasselblad V, Hedges LV: Meta-analysis of screening and diagnostic tests. Psychol Bull 117:167-178, 1995

39. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200-2205, 2000

40. Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115-1121, 2000

41. Martinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496-502, 1997

42. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D’Amour P: Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 46:697-703, 2000

43. Yumita S, Suzuki M, Akiba T, Akizawa T, Seino Y, Kurokawa K: Levels of serum 1,25(OH)2D in patients with pre-dialysis chronic renal failure. Tohoku J Exp Med 180:45-56, 1996

44. Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM, LeBoff MS: Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 57:329-335, 1995

45. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6:162-169, 1991

46. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67:876-881, 1988

47. Shin SK, Kim DH, Kim HS, Shin KT, Ma KA, Kim SJ, Kwak YS, Ha SK, Sherrard DJ: Renal osteodystrophy in pre-dialysis patients: Ethnic difference? Perit Dial Int 19:S402-S407, 1999 (suppl 2)

48. Malluche HH, Ritz E, Hodgson M, Kutschera J, Krause G, Seiffert U, Gati A, Lange HP: Skeletal lesions and calcium metabolism in early renal failure. Proc Eur Dial Transplant Assoc 11:443-450, 1975

49. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW: Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 41:339-345, 1975

50. Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, Schoeppe W: Bone histology in incipient and advanced renal failure. Kidney Int 9:355-362, 1976

51. Sherrard DJ, Baylink DJ, Wergedal JE, Maloney NA: Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab 39:119-135, 1974

52. Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A: Renal osteodystrophy in dialysis patients: Diagnosis and treatment. Artif Organs 22:530-557, 1998

53. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F: Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 11:813-819, 1996

54. Smith AJ, Faugere MC, Abreo K, Fanti P, Julian B, Malluche HH: Aluminum-related bone disease in mild and advanced renal failure: Evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 6:275-283, 1986

55. Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A: Adynamic bone disease with negative aluminum staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 9:517-523, 1994

56. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D: Renal osteodystrophy in diabetic patients. Kidney Int 44:159-164, 1993

57. Andress DL, Hercz G, Kopp JB, Endres DB, Norris KC, Coburn JW, Sherrard DJ: Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 2:525-531, 1987

58. Carmen Sanchez M, Auxiliadora Bajo M, Selgas R, Mate A, Millan I, Eugenia Martinez M, Lopez-Barea F: Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 36:953-961, 2000

59. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D: Risk factors for renal osteodystrophy: A multivariant analysis. J Bone Miner Res 10:149-156, 1995

60. Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R: Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 14:19-29, 1994

61. Malluche HH, Monier-Faugere MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 38:S62-S67, 1992

62. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993

63. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H: Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 55:1019-1027, 1999

64. Martinez I, Saracho R, Montenegro J, Llach F: A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 11:22-28, 1996 (suppl 3)

65. Messa P, Vallone C, Mioni G, Geatti O, Turrin D, Passoni N, Cruciatti A: Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. Kidney Int 46:1713-1720, 1994

66. Christiansen C, Christensen MS, Melsen F, Rodbro P, DeLuca HF: Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D. Clin Nephrol 15:18-22, 1981

67. Tessitore N, Venturi A, Adami S, Roncari C, Rugiu C, Corgnati A, Bonucci E, Maschio G: Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure. Miner Electrolyte Metab 13:38-44, 1987

68. Malluche HH, Monier-Faugere MC: The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 4:1631-1642, 1994

69. Faugere MC, Malluche HH: Stainable aluminum and not aluminum content reflects bone histology in dialyzed patients. Kidney Int 30:717-722, 1986

70. Teitelbaum SL: Renal osteodystrophy. Hum Pathol 15:306-323, 1984

71. Malluche HH, Langub MC, Monier-Faugere MC: Pathogenesis and histology of renal osteodystrophy. Osteoporos Int 7:S184-S187, 1997 (suppl 3)

72. Malluche HH, Langub MC, Monier-Faugere MC: The role of bone biopsy in clinical practice and research. Kidney Int Suppl 73:S20-S25, 1999

73. Freemont T: Histological diagnosis of renal osteodystrophy. Kidney Int Suppl 73:S26-S30, 1999

74. Couttenye MM, D’Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME: High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 12:2144-2150, 1997

75. Coburn JW: Mineral metabolism and renal bone disease: Effects of CAPD versus hemodialysis. Kidney Int Suppl 40:S92-S100, 1993

76. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396-399, 2000

77. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293, 1999

78. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610, 1987

79. Maloney NA, Ott SM, Alfrey AC, Miller NL, Coburn JW, Sherrard DJ: Histological quantitation of aluminum in iliac bone from patients with renal failure. J Lab Clin Med 99:206-216, 1982

80. Cournot-Witmer G, Zingraff J, Plachot JJ, Escaig F, Lefevre R, Boumati P, Bourdeau A, Garabedian M, Galle P, Bourdon R, Drueke T, Balsan S: Aluminum localization in bone from hemodialyzed patients: Relationship to matrix mineralization. Kidney Int 20:375-378, 1981

81. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287-4290, 1999

82. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460-1468, 2001

83. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761, 2000

84. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96:1786-1793, 1995

85. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ: Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996

86. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S: Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl 71:S238-S241, 1999

87. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000

88. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324-332, 2001

89. Ahmed S, O’Neill KD, Hood AF, Evan AP, Moe SM: Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 37:1267-1276, 2001

90. Marchais SJ, Metivier F, Guerin AP, London GM: Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 14:2178-2183, 1999

91. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000

92. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998

93. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990

94. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938-942, 2001

95. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001

96. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-E17, 2000

97. Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG: Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 85:651-657, 1988

98. Katz AI, Hampers CL, Merrill JP: Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Analysis of 195 patients, with observations on the effects of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Medicine (Baltimore) 48:333-374, 1969

99. Raggi P, Reinmuller R, Chertow GM: Cardiac calcification is prevalent and severe in ESRD patients as measured by electron beam CT scanning. J Am Soc Nephrol 75A, 2000 (abstr A0405)

100. Greene SV, Falciglia G, Rademacher R: Relationship between serum phosphorus levels and various outcome measures in adult hemodialysis patients. J Ren Nutr 8:77-82, 1998

101. Lopez-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 259:F432-F437, 1990

102. Combe C, Deforges-Lasseur C, Caix J, Pommereau A, Marot D, Aparicio M: Compliance and effects of nutritional treatment on progression and metabolic disorders of chronic renal failure. Nephrol Dial Transplant 8:412-418, 1993

103. Recker RR, Saville PD: Calcium absorption in renal failure: Its relationship to blood urea nitrogen, dietary calcium intake, time on dialysis, and other variables. J Lab Clin Med 78:380-388, 1971

104. Hosking DJ, Chamberlain MJ: Calcium balance in chronic renal failure. A study using in vivo neutron activation analysis. Q J Med 42:467-479, 1973

105. Duursma SA, Visser WJ, Mees EJ, Njio L: Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Calcif Tissue Res 16:129-138, 1974

106. Better OS, Kleeman CR, Gonick HC, Varrady PD, Maxwell MH: Renal handling of calcium, magnesium and inorganic phosphate in chronic renal failure. Isr J Med Sci 3:60-79, 1967

107. Suzuki M, Hirasawa Y: Renal osteodystrophy in early chronic renal failure. Contrib Nephrol 22:28-38, 1980

108. Cochran M, Bulusu L, Horsman A, Stasiak L, Nordin BE: Hypocalcaemia and bone disease in renal failure. Nephron 10:113-140, 1973

109. Reduction of dietary protein and phosphorus in the Modification of Diet in Renal Disease Feasibility Study. The MDRD Study Group. J Am Diet Assoc 94:986-990; [quiz 991-982], 1994

110. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324:78-84, 1991

111. Williams PS, Stevens ME, Fass G, Irons L, Bone JM: Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. Q J Med 81:837-855, 1991

112. Mahmoud MD, Bouche V, Collin P, Girault A: Effects of keto-analogues on phosphocalcic and aminoacid metabolism in dialysed patients: A crossover study. Int J Artif Organs 12:692-696, 1989

113. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994

114. The Modification of Diet in Renal Disease Study: Design, methods, and results from the feasibility study. Am J Kidney Dis 20:18-33, 1992

115. Malvy D, Maingourd C, Pengloan J, Bagros P, Nivet H: Effects of severe protein restriction with ketoanalogues in advanced renal failure. J Am Coll Nutr 18:481-486, 1999

116. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O: Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 349:1117-1123, 1997

117. Herselman MG, Albertse EC, Lombard CJ, Swanepoel CR, Hough FS: Supplemented low-protein diets—Are they superior in chronic renal failure? S Afr Med J 85:361-365, 1995

118. D’Amico G, Gentile MG, Fellin G, Manna G, Cofano F: Effect of dietary protein restriction on the progression of renal failure: A prospective randomized trial. Nephrol Dial Transplant 9:1590-1594, 1994

119. Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ: Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 16:483-492, 1993

120. Kist-van Holthe tot Echten JE, Nauta J, Hop WC, de Jong MC, Reitsma-Bierens WC, Ploos van Amstel SL, van Acker KJ, Noordzij CM, Wolff ED: Protein restriction in chronic renal failure. Arch Dis Child 68:371-375, 1993

121. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A: Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 337:1299-1304, 1991

122. Forget D, Caranhac G, Quillot MJ, Besnier MO: Compliance with very low protein diet and ketoanalogues in chronic renal failure. The French Multicentric Trial IRCCA. Contrib Nephrol 81:79-86, 1990

123. Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-Smith PS: The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 321:1773-1777, 1989

124. Ando A, Orita Y, Nakata K, Fukuhara Y, Mikami H, Fujii M, Nakajima Y, Ueda N, Abe H: The effect of essential amino acid supplementation therapy on prognosis of patients with chronic renal failure estimated on the basis of the Markov process. Med J Osaka Univ 32:31-37, 1981

125. Barsotti G, Lazzeri M, Polloni A, Morelli E, Giovannetti E, Lupetti S, Cupisti A, Dani L, Giovannetti S: Effects of the impairment of renal function and of the pH of gastric secretion on the efficacy of Al(OH)3 to reduce serum inorganic phosphorus. Adv Exp Med Biol 208:493-499, 1986

126. Meisinger E, Strauch M: Controlled trial of two keto acid supplements on renal function, nutritional status, and bone metabolism in uremic patients. Kidney Int Suppl 22:S170-S173, 1987

127. Schmicker R, Vetter K, Lindenau K, Frohling PT, Kokot F: Conservative long-term treatment of chronic renal failure with keto acid and amino acid supplementation. Infusionsther Klin Ernahr 14:34-38, 1987 (suppl 5)

128. Gentile MG, Manna GM, Ferrario L, D’Amico G: Preliminary experience on dietary management of chronic renal failure. Contrib Nephrol 53:102-108, 1986

129. Drueke TB: Primary and secondary uraemic hyperparathyroidism: From initial clinical observations to recent findings. Nephrol Dial Transplant 13:1384-1387, 1998

130. Popovtzer MM, Massry SG, Makoff DL, Maxwell MH, Kleeman CR: Renal handling of phosphate in patients with chronic renal failure. The role of variations in serum phosphorus and parathyroid activity. Isr J Med Sci 5:1018-1023, 1969

131. London GM, Pannier B, Marchais SJ, Guerin AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 11:778-783, 2000

132. Milas NC, Nowalk MP, Akpele L, Castaldo L, Coyne T, Doroshenko L, Kigawa L, Korzec-Ramirez D, Scherch LK, Snetselaar L: Factors associated with adherence to the dietary protein intervention in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 95:1295-1300, 1995

133. Foret M, Renversez JC, Meftahi H, Kuentz F, Milongo R, Hachache T, Vallin J, Dechelette E, Cordonnier D: How far can plasmatic levels of beta-2-microglobulin in hemodialysis be relied upon? Contrib Nephrol 62:54-59, 1988

134. Jureidini KF, Hogg RJ, van Renen MJ, Southwood TR, Henning PH, Cobiac L, Daniels L, Harris S: Evaluation of long-term aggressive dietary management of chronic renal failure in children. Pediatr Nephrol 4:1-10, 1990

135. Uauy RD, Hogg RJ, Brewer ED, Reisch JS, Cunningham C, Holliday MA: Dietary protein and growth in infants with chronic renal insufficiency: A report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. Pediatr Nephrol 8:45-50, 1994

136. Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR, Zimmer GS: Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 52:778-791, 1997

137. Coggins CH, Dwyer JT, Greene T, Petot G, Snetselaar LG, Van Lente F: Serum lipid changes associated with modified protein diets: Results from the feasibility phase of the Modification of Diet in Renal Disease Study. Am J Kidney Dis 23:514-523, 1994

138. Cianciaruso B, Capuano A, D’Amaro E, Ferrara N, Nastasi A, Conte G, Bellizzi V, Andreucci VE: Dietary compliance to a low protein and phosphate diet in patients with chronic renal failure. Kidney Int Suppl 27:S173-S176, 1989

139. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690-695, 1989

140. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS: Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320:1110-1113, 1989

141. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986

142. Balasa RW, Murray RL, Kondelis NP, Bischel MD: Phosphate-binding properties and electrolyte content of aluminum hydroxide antacids. Nephron 45:16-21, 1987

143. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB: Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 17:544-550, 1991

144. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS: Reduction of dietary phosphorus absorption by phosphorus binders: A theoretical, in vitro, and in vivo study. J Clin Invest 83:66-73, 1989

145. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI: Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 12:961-964, 1997

146. Alfrey AC: Aluminum intoxication. N Engl J Med 310:1113-1115, 1984

147. Andreoli SP, Bergstein JM, Sherrard DJ: Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 310:1079-1084, 1984

148. Raj DS, Charra B, Pierratos A, Work J: In search of ideal hemodialysis: is prolonged frequent dialysis the answer? Am J Kidney Dis 34:597-610, 1999

149. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404, 1998

150. Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ: Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study. Nephrol Dial Transplant 14:1475-1479, 1999

151. Lerner A, Kramer M, Goldstein S, Caruana R, Epstein S, Raja R: Calcium carbonate. A better phosphate binder than aluminum hydroxide. ASAIO Trans 32:315-318, 1986

152. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999

153. Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP: Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 45:111-119, 1996

154. Pflanz S, Henderson IS, McElduff N, Jones MC: Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant 9:1121-1124, 1994

155. Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ: Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: A controlled study. Nephrol Dial Transplant 8:341-346, 1993

156. Caravaca F, Fernandez MA, Ruiz-Calero R, Cubero J, Aparicio A, Jimenez F, Garcia MC: Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 13:2605-2611, 1998

157. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E: Poly[allylamine hydrochloride](RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997

158. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E: Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 49:163-167, 1996

159. van den Bergh JP, Gelens MA, Klaassen HA, Kaufmann BG, Bottger WM, Verstappen VM: Efficacy and tolerance of three different calcium acetate formulations in hemodialysis patients. Neth J Med 55:222-228, 1999

160. Tan SY, Irish A, Winearls CG, Brown EA, Gower PE, Clutterbuck EJ, Madhoo S, Lavender JP, Pepys MB, Hawkins PN: Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 50:282-289, 1996

161. Ittel TH, Schafer C, Schmitt H, Gladziwa U, Sieberth HG: Calcium carbonate as a phosphate binder in dialysis patients: Evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia. Klin Wochenschr 69:59-67, 1991

162. Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B: Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis 31:257-262, 1998

163. Jespersen B, Jensen JD, Nielsen HK, Lauridsen IN, Andersen MJ, Poulsen JH, Gammelgaard B, Pedersen EB: Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients. Nephrol Dial Transplant 6:98-104, 1991

164. Bame SI, Petersen N, Wray NP: Variation in hemodialysis patient compliance according to demographic characteristics. Soc Sci Med 37:1035-1043, 1993

165. Coyne T, Olson M, Bradham K, Garcon M, Gregory P, Scherch L: Dietary satisfaction correlated with adherence in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 95:1301-1306, 1995

166. Cleary DJ, Matzke GR, Alexander AC, Joy MS: Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm 52:1895-1900, 1995

167. Morduchowicz G, Sulkes J, Aizic S, Gabbay U, Winkler J, Boner G: Compliance in hemodialysis patients: A multivariate regression analysis. Nephron 64:365-368, 1993

168. Weed-Collins M, Hogan R: Knowledge and health beliefs regarding phosphate-binding medication in predicting compliance. Anna J 16:278-282285, discussion 286, 1989

169. Cummings KM, Becker MH, Kirscht JP, Levin NW: Psychosocial factors affecting adherence to medical regiments in a group of hemodialysis patients. Med Care 20:567-580, 1982

170. Blackburn SL: Dietary compliance of chronic hemodialysis patients. J Am Diet Assoc 70:31-37, 1977

171. Coburn JW, Mischel MG, Goodman WG, Salusky IB: Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 17:708-711, 1991

172. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26, 1999

173. Chertow GM, Dillon MA, Amin N, Burke SK: Sevelamer with and without calcium and vitamin D: Observations from a long-term open-label clinical trial. J Ren Nutr 10:125-132, 2000

174. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861, 1994

175. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002

176. Nordin BEC: Nutritional consideration, in Nordin BEC (ed): Calcium, Phosphate and Magnesium Metabolism. New York, NY, Churchill Livingston, 1976, pp 3-35

177. Elin RJ: Laboratory reference intervals and values, in Goldman L, Bennett JC (eds): Cecil Textbook of Medicine (ed 21). Philadelphia, PA, Saunders, 2000, pp 2299-2308

178. Enders DB, Rude RK: Mineral and bone metabolism, in Burtis CA, Ashwood ER (ed): Tietz Fundamentals of Clinical Chemistry (ed 5). Philadelphia, PA, Saunders, 2001, pp 795-821

179. Portale AA: Blood calcium, phosphorus, and magnesium, in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, PA, Lippincott, Williams & Wilkins, 1999, pp 115-118

180. Institute of Medicine: Dietary References Intakes: Calcium, Phosphorus, Magnesium, Vitamin D3, and Fluoride. Washington, DC, National Academy Press, 1997

181. Lemann J, Favus MJ: The intestinal absorption of calcium, magnesium, and phosphate, in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, PA, Lippincott, Williams & Wilkins, 1999, pp 63-67

182. Brickman AS, Coburn JW, Massry SG, Norman AW: 1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure. Ann Intern Med 80:161-168, 1974

183. Shane E: Hypercalcemia; pathogenesis, clinical manifestation, differential diagnosis and management, in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, PA, Lippincott, Williams & Wilkins, 1999, pp 183-187

184. Massry SG, Smogorzewski M: Dyscalcemias, in Massry SG, Glassock RJ (eds): Massry and Glassock’s Textbook of Nephrology. Philadelphia, PA, Lippincott, Williams & Wilkins, 2001, 326-340

185. Fernandez E, Montoliu J: Successful treatment of massive uraemic tumoral calcinosis with daily haemodialysis and very low calcium dialysate. Nephrol Dial Transplant 9:1207-1209, 1994

186. Clase CM, Norman GL, Beecroft ML, Churchill DN: Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant 15:1841-1846, 2000

187. Morton AR, Hercz G: Hypercalcemia in dialysis patients: Comparison of diagnostic methods. Dial Transplant 20:661-667, 1991

188. Coburn JW, Popovtzer MM, Massry SG, Kleeman CR: The physicochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med 124:302-311, 1969

189. Wasler M: The separate effects of hyperparathyroidism, hypercalcemia of malignancy, renal failure and acidosis on the state of calcium phosphate and other ions in plasma. J Clin Invest 41:1454-1464, 1962

190. Campos C, Arata RO, Mautalen CA: Parathyroid hormone and vertebral osteosclerosis in uremic patients. Metabolism 25:495-501, 1976

191. Fuss M, De Backer M, Brauman J, Nijs-Dewolf N, Manderlier T, Brauman H, Corvilain J: Parathyroid hormone plasma level in untreated chronic renal failure and in hemodialyzed patients. Nephron 17:144-154, 1976

192. Malhotra KK, Gadekar NG, Umashankar P, Bhargava S: Bone disease in chronic renal failure. Indian J Med Res 56:1687-1695, 1968

193. Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O’Dea R, Murray DC, Barre PE: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 16:386-393, 1996

194. Malluche HH, Werner E, Ritz E: Intestinal calcium absorption and whole-body calcium retention incipient and advanced renal failure. Miner Electrolyte Metab 1:263-270, 1978

195. Coburn JW, Koppel MH, Brickman AS, Massry SG: Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3:264-272, 1973

196. Wiegmann TB, Kaye M: Malabsorption of calcium and phosphate in chronic renal failure: 32P and 45Ca studies in dialysis patients. Clin Nephrol 34:35-41, 1990

197. Mountokalakis TH, Singhellakis PN, Alevizaki CC, Virvidakis K, Ikkos DG: Relationship between degree of renal failure and impairment of intestinal calcium absorption. Nephron 16:20-30, 1976

198. Kopple JD, Coburn JW: Metabolic studies of low protein diets in uremia. II. Calcium, phosphorus and magnesium. Medicine (Baltimore) 52:597-607, 1973

199. Popovtzer MM, Michael UF, Johnson-Dial KS, Ronstadt C, Nelson D, Ogden DA: Dietary calcium deprivation and secondary hyperparathyroidism in patients treated with chronic dialysis. Miner Electrolyte Metab 12:298-302, 1986

200. Trachtman H, Chan JC, Boyle R, Farina D, Baluarte HJ, Chinchilli VM, Dresner IG, Feld LG: The relationship between calcium, phosphorus, and sodium intake, race, and blood pressure in children with renal insufficiency: A report of the Growth Failure in Children with Renal Diseases (GFRD) Study. J Am Soc Nephrol 6:126-131, 1995

201. Clarkson EM, Eastwood JB, Koutsaimanis KG, de Wardener HE: Net intestinal absorption of calcium in patients with chronic renal failure.Kidney Int 3:258-263, 1973

202. Friis T, Hahnemann S, Weeke E: Serum calcium and serum phsophorus in uraemia during administration of osdium phytate and aluminium hydroxide. Acta Med Scand 183:497-505, 1968

203. Hercz G, Kraut JA, Andress DA, Howard N, Roberts C, Shinaberger JH, Sherrard DJ, Coburn JW: Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab 12:314-319, 1986

204. Moriniere P, Fournier A, Leflon A, Herve M, Sebert JL, Gregoire I, Bataille P, Gueris J: Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 39:309-315, 1985

205. Petersen LJ, Rudnicki M, Hojsted J: Long-term oral calcium supplementation reduces diastolic blood pressure in end stage renal disease. A randomized, double-blind, placebo controlled study. Int J Artif Organs 17:37-40, 1994

206. Saha H, Pietila K, Mustonen J, Pasternack A, Morsky P, Seppala E, Reinikainen P: Acute effects of calcium carbonate and citrate on secondary hyperparathyroidism in chronic renal failure. Am J Nephrol 11:465-469, 1991

207. Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis JR: Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2:875-877, 1987

208. Fernandez-Reyes MJ, Auxiliadora Bajo M, Robles P, Selgas R, Oliver J, Del Peso G, Garcia G, Jimenez C, Garcia-Gallego F: Mitral annular calcification in CAPD patients with a low degree of hyperparathyroidism. An analysis of other possible risk factors. Nephrol Dial Transplant 10:2090-2095, 1995

209. Valentzas C, Meindok H, Oreopoulos DG, Meema HK, Rabinovich S, Jones M, Sutton D, Rapaport A, deVeber GA: Visceral calcification and Ca-P product. Adv Exp Med Biol 103:187-193, 1978

210. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037-2040, 1998

211. Cassidy MJ, Owen JP, Ellis HA, Dewar J, Robinson CJ, Wilkinson R, Ward MK, Kerr DN: Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med 54:29-48, 1985

212. Bouillon RA, Auwerx JH, Lissens WD, Pelemans WK: Vitamin D status in the elderly: Seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am J Clin Nutr 45:755-763, 1987

213. Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P: Prevention of bone loss by vitamin D supplementation in elderly women: A randomized double-blind trial. J Clin Endocrinol Metab 80:1052-1058, 1995

214. Khaw KT, Sneyd MJ, Compston J: Bone density, parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. Br Med J 305:373-376, 1992

215. Eastwood JB, Stamp TC, De Wardener HE, Bordier PJ, Arnaud CD: The effect of 25-hydroxy vitamin D3 in the osteomalacia of chronic renal failure. Clin Sci Mol Med 52:499-508, 1977

216. Eastwood JB, Stamp TC, Harris E, de Wardener HE: Vitamin-D deficiency in the osteomalacia of chronic renal failure. Lancet 2:1209-1211, 1976

217. Chapuy MC, Meunier PJ: Vitamin D insufficiency in adults and the elderly, in Feldman D, Glorieux FH, Pike JW (eds): Vitamin D. San Diego, CA, Academic, 1997, pp 679-693

218. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS: Hypovitaminosis D in medical inpatients. N Engl J Med 338:777-783, 1998

219. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J: Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 281:1505-1511, 1999

220. Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB: Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 41:161-165, 1992

221. Papapoulos SE, Clemens TL, Fraher LJ, Gleed J, O’Riordan JL: Metabolites of vitamin D in human vitamin-D deficiency: Effect of vitamin D3 or 1,25-dihydroxycholecalciferol. Lancet 2:612-615, 1980

222. Holick MF: Vitamin D and the kidney. Kidney Int 32:912-929, 1987

223. Holick MF, Matsuoka LY, Wortsman J: Age, vitamin D, and solar ultraviolet. Lancet 2:1104-1105, 1989

224. Clemens TL, Adams JS, Henderson SL, Holick MF: Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1:74-76, 1982

225. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ: Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439-443, 1997

226. Saha H: Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 41:290-296, 1994

227. Kinyamu HK, Gallagher JC, Balhorn KE, Petranick KM, Rafferty KA: Serum vitamin D metabolites and calcium absorption in normal young and elderly free-living women and in women living in nursing homes. Am J Clin Nutr 65:790-797, 1997

228. Webb AR, Pilbeam C, Hanafin N, Holick MF: An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr 51:1075-1081, 1990

229. Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A: Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 55:2169-2177, 1999

230. Lambert PW, Stern PH, Avioli RC, Brackett NC, Turner RT, Greene A, Fu IY, Bell NH: Evidence for extrarenal production of 1 alpha,25-dihydroxyvitamin D in man. J Clin Invest 69:722-725, 1982

231. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368-375, 1988

232. Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, Slatopolsky E: Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72:157-164, 1991

233. Food and Nutrition Board. National Research Council. National Academy of Sciences. Recommended Daily Allowances (ed 10). Washington, DC, National Academy Press, 1989

234. Food and Nutrition Board. National Research Council. National Academy of Sciences. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC, National Academy Press, 1997

235. Shah BR, Finberg L: Single-day therapy for nutritional vitamin D-deficiency rickets: A preferred method. J Pediatr 125:487-490, 1994

236. Kruse K: Pathophysiology of calcium metabolism in children with vitamin D-deficiency rickets. J Pediatr 126:736-741, 1995

237. Combe C, Aparicio M: Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46:1381-1386, 1994

238. Lafage MH, Combe C, Fournier A, Aparicio M: Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42:1217-1225, 1992

239. Coburn JW, Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Knutson JC, Bishop CW: 1 alpha-Hydroxy-vitamin D2: A new look at an ’old’ compound. Nephrol Dial Transplant 11:153-157, 1996 (suppl 3)

240. Harrington DD, Page EH: Acute vitamin D3 toxicosis in horses: Case reports and experimental studies of the comparative toxicity of vitamins D2 and D3. J Am Vet Med Assoc 182:1358-1369, 1983

241. van der Wielen RP, Lowik MR, van den Berg H, de Groot LC, Haller J, Moreiras O, van Staveren WA: Serum vitamin D concentrations among elderly people in Europe. Lancet 346:207-210, 1995

242. Lips P, van Ginkel FC, Jongen MJ, Rubertus F, van der Vijgh WJ, Netelenbos JC: Determinants of vitamin D status in patients with hip fracture and in elderly control subjects. Am J Clin Nutr 46:1005-1010, 1987

243. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637-1642, 1992

244. Prince RL, Hutchison BG, Kent JC, Kent GN, Retallack RW: Calcitriol deficiency with retained synthetic reserve in chronic renal failure. Kidney Int 33:722-728, 1988

245. Rickers H, Christiansen C, Christensen P, Christensen M, Rodbro P: Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron 39:267-271, 1985

246. Nordal KP, Dahl E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67:929-936, 1988

247. Coen G, Mazzaferro S, Bonucci E, Ballanti P, Massimetti C, Donato G, Landi A, Smacchi A, Della Rocca C, Cinotti GA, et al: Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: Humoral and histomorphometric results. Miner Electrolyte Metab 12:375-382, 1986

248. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G: Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9:1595-1599, 1994

249. Portale AA, Booth BE, Halloran BP, Morris RC Jr: Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580-1589, 1984

250. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296-1301, 1986

251. Przedlacki J, Manelius J, Huttunen K: Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 69:433-437, 1995

252. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH: 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661-669, 1989

253. Nordal KP, Dahl E, Halse J, Attramadal A, Flatmark A: Long-term low-dose calcitriol treatment in predialysis chronic renal failure: Can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant 10:203-206, 1995

254. Coen G, Mazzaferro S, Manni M, Napoletano I, Fondi G, Sardella D, Perruzza I, Pasquali M, Taggi F: Treatment with small doses of 1,25-dihydroxyvitamin D in predialysis chronic renal failure may lower the rate of decline of renal function. Ital J Miner Electrolyte Metab 8:117-121, 1994

255. Jensen GF, Christiansen C, Transbol I: 1,25(OH)2D3 and renal function. A controlled clinical study in normal elderly women. Acta Med Scand 211:51-54, 1982

256. Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G: Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 33:98-102, 1990

257. Perez A, Raab R, Chen TC, Turner A, Holick MF: Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134:1070-1078, 1996

258. Kanis JA, Cundy T, Earnshaw M, Henderson RG, Heynen G, Naik R, Russell RG, Smith R, Woods CG: Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses. Q J Med 48:289-322, 1979

259. Naik RB, Cundy T, Robinson BH, Russell RG, Kanis JA: Effects of vitamin D metabolites and analogues on renal function. Nephron 28:17-25, 1981

260. Nielsen HE, Romer FK, Melsen F, Christensen MS, Hansen HE: 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Clin Nephrol 13:103-108, 1980

261. Brickman AS, Coburn JW, Sherrard DJ, Wong EG, Norman AW, Singer FR: Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy. Contrib Nephrol 18:29-41, 1980

262. Kanis JA, Russell RG, Cundy T, Earnshaw M, Woods CG, Smith R, Heynen G: An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease. Contrib Nephrol 18:12-28, 1980

263. Berl T, Berns AS, Huffer WE, Alfrey AC, Arnaud CD, Schrier RR: Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis. Contrib Nephrol 18:72-81, 1980

264. Peacock M, Aaron JE, Walker GS, Davison AM: Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3. Clin Endocrinol (Oxf) 7:73s-81s, 1977 (suppl)

265. Herrmann P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Nonnast-Daniel B, Koch KM, Weber U, Horl W, Haas-Worle A, et al: Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 67:48-53, 1994

266. Papapoulos SE, Brownjohn AM, Junor BJ, Marsh FP, Goodwin FJ, Hately W, Lewin IG, Tomlinson S, Hendy GN, O’Riordan JL: Hyperparathyroidism in chronic renal failure. Clin Endocrinol (Oxf) 7:59s-65s, 1977 (suppl)

267. Moriniere P, Esper NE, Viron B, Judith D, Bourgeon B, Farquet C, Gheerbrandt JD, Chapuy MC, Orshoven AV, Pamphile R, Fournier A: Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1-alpha(OH) vitamin D3, oral CaCo3 and low dialysate calcium. Kidney Int 43:S121-S124, 1993 (suppl 41)

268. Morii H, Ogura Y, Koshikawa S, Mimura N, Suzuki M, Kurokawa K, Marumo F, Kawaguchi Y, Maeda K, Nishizawa Y, Inoue S, Fujima S: Efficacy and safety of oral falecalcitrol in reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. J Bone Miner Metab 16, 1988

269. Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 36:550-561, 2000

270. Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: A sequential comparison. Am J Kidney Dis 37:532-543, 2001

271. Sherrard DJ, Coburn JW, Brickman AS, Singer FR, Maloney N: Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure. Contrib Nephrol 18:92-97, 1980

272. Krempien B, Ritz E, Tschope W: The effect of 1,25 (OH)2D3 on bone mineralization: Ultrastructural studies in patients with renal osteodystrophy. Contrib Nephrol 18:122-134, 1980

273. Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW: Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317-323, 1997

274. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150, 1992

275. Sprague SM, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 19:532-539, 1992

276. Cannella G, Bonucci E, Rolla D, Ballanti P, Moriero E, De Grandi R, Augeri C, Claudiani F, Di Maio G: Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 46:1124-1132, 1994

277. Dressler R, Laut J, Lynn RI, Ginsberg N: Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 43:324-331, 1995

278. Llach F, Hervas J, Cerezo S: The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 26:845-851, 1995

279. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436-1443, 1993

280. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68:221-228, 1994

281. Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Kitaoka M, Harada S, Sekine N, Matsumoto T, Kurokawa K: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 323:421-422, 1990

282. Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kikawada R, Marumo F: The ‘oral 1,25-dihydroxyvitamin D3 pulse therapy’ in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57:23-28, 1991

283. Muramoto H, Haruki K, Yoshimura A, Mimo N, Oda K, Tofuku Y: Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of 1,25(OH)2vitamin D3. Nephron 58:288-294, 1991

284. Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, Goodwin FJ, Marsh FP, Adami S, Hately W, et al: Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 26:185-191, 1986

285. Memmos DE, Eastwood JB, Talner LB, Gower PE, Curtis JR, Phillips ME, Carter GD, Alaghband-Zadeh J, Roberts AP, de Wardener HE: Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) 282:1919-1924, 1981

286. Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F: ‘Pulse oral’ versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. Nephron 77:267-272, 1997

287. Indridason OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 57:282-292, 2000

288. Fischer ER, Harris DC: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 40:216-220, 1993

289. Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M: Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 20:97-102, 1994

290. Caravaca F, Cubero JJ, Jimenez F, Lopez JM, Aparicio A, Cid MC, Pizarro JL, Liso J, Santos I: Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism. Nephrol Dial Transplant 10:665-670, 1995

291. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710-1721, 1994

292. Levine BS, Song M: Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 7:488-496, 1996

293. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 42:1191-1198, 1992

294. Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M: Safety and efficacy of pulse and daily calcitriol in patients on CAPD: A randomized trial. Nephrol Dial Transplant 13:1234-1241, 1998

295. Brown AJ, Slatopolsky E: Vitamin D analogs: Perspectives for treatment. Miner Electrolyte Metab 25:337-341, 1999

296. Slatopolsky E, Dusso A, Brown A: New analogs of vitamin D3. Kidney Int Suppl 73:S46-S51, 1999

297. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E: Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study. Nephrol Dial Transplant 11:121-124, 1996 (suppl 3)

298. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y: Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32:238-246, 1998

299. Taga T: The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Ann Med 29:63-72, 1997

300. Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, DeLuca H: A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995

301. Nishii Y, Abe J, Mori T, Brown AJ, Dusso AS, Finch J, Lopez-Hilker S, Morrissey J, Slatopolsky E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. Contrib Nephrol 91:123-128, 1991

302. Sjoden G, Lindgren JU, DeLuca HF: Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats. J Nutr 114:2043-2046, 1984

303. Sjoden G, Smith C, Lindgren U, DeLuca HF: 1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 178:432-436, 1985

304. Gallagher JC, Bishop CW, Knutson JC, Mazess RB, DeLuca HF: Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women. J Bone Miner Res 9:607-614, 1994

305. Weber K, Goldberg M, Stangassinger M, Erben RG: 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats. J Bone Miner Res 16:639-651, 2001

306. Vlassopoulos D, Noussias C, Revenas K, Hadjilouka-Mantaka A, Arvanitis D, Tzortzis G, Hadjiconstantinou V: Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism. Ren Fail 21:199-207, 1999

307. Martinez ME, Selgas R, Miguel JL, Balaguer G, Sanchez-Cabezudo MJ, Llach F: Osteocalcin levels in uremic patients: influence of calcitriol treatment through two different routes and type of dialysis. Nephron 59:429-433, 1991

308. Morita A, Tabata T, Inoue T, Nishizawa Y, Morii H: The effect of oral 1 alpha-hydroxycalciferol treatment on bone mineral density in hemodialysis patients. Clin Nephrol 46:389-393, 1996

309. Shimamatsu K, Maeda T, Harada A, Nishitani H, Onoyama K, Fujimi S, Omae T: 1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis. Nephron 28:70-75, 1981

310. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166, 1994

311. Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205-211, 1998

312. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989

313. Kanis JA, Russell RG, Naik RB, Earnshaw M, Smith R, Heynen G, Woods CG: Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease. Clin Endocrinol (Oxf) 7:51s-57s, 1977 (suppl)

314. Malluche HH, Goldstein DA, Massry SG: Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients. Contrib Nephrol 18:98-104, 1980

315. Delling G, Luhmann H, Bulla M, Fuchs C, Henning HV, Jansen JL, Kohnle W, Schulz W: The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure. Contrib Nephrol 18:105-121, 1980

316. Johnson WJ, Goldsmith RS, Beabout JW, Jowsey J, Kelly PJ, Arnaud CD: Prevention and reversal of progressive secondary hyperparathyroidism in patients maintained by hemodialysis. Am J Med 56:827-832, 1974

317. Sherrard DJ: Aluminum—Much ado about something. N Engl J Med 324:558-559, 1991

318. Morrissey J, Rothstein M, Mayor G, Slatopolsky E: Suppression of parathyroid hormone secretion by aluminum. Kidney Int 23:699-704, 1983

319. Ott SM, Maloney NA, Coburn JW, Alfrey AC, Sherrard DJ: The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 307:709-713, 1982

320. Windus DW, Stokes TJ, Julian BA, Fenves AZ: Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med 107:678-680, 1987

321. Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J: High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: Effective phosphate control and aluminium avoidance in haemodialysis patients. Nephrol Dial Transplant 4:105-109, 1989

322. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK: Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 13:2303-2310, 1998

323. Morrison G, Michelson EL, Brown S, Morganroth J: Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int 17:811-819, 1980

324. Nappi SE, Virtanen VK, Saha HH, Mustonen JT, Pasternack AI: QTc dispersion increases during hemodialysis with low-calcium dialysate. Kidney Int 57:2117-2122, 2000

325. Sprague SM, Moe SM: Clinical manifestations and pathogenesis of dialysis-related amyloidosis. Semin Dial 9:360-369, 1996

326. Zingraff JJ, Noel LH, Bardin T, Atienza C, Zins B, Drueke TB, Kuntz D: Beta 2-microglobulin amyloidosis in chronic renal failure. N Engl J Med 323:1070-1071, 1990

327. Campistol JM, Cases A, Torras A, Soler M, Munoz-Gomez J, Montoliu J, Lopez-Pedret J, Revert L: Visceral involvement of dialysis amyloidosis. Am J Nephrol 7:390-393, 1987

328. Campistol JM, Sole M, Munoz-Gomez J, Lopez-Pedret J, Revert L: Systemic involvement of dialysis-amyloidosis. Am J Nephrol 10:389-396, 1990

329. Gal R, Korzets A, Schwartz A, Rath-Wolfson L, Gafter U: Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature. Arch Pathol Lab Med 118:718-721, 1994

330. Benz RL, Siegfried JW, Teehan BP: Carpal tunnel syndrome in dialysis patients: Comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations. Am J Kidney Dis 11:473-476, 1988

331. Cornelis F, Bardin T, Faller B, Verger C, Allouache M, Raymond P, Rottembourg J, Tourliere D, Benhamou C, Noel LH, et al: Rheumatic syndromes and beta 2-microglobulin amyloidosis in patients receiving long-term peritoneal dialysis. Arthritis Rheum 32:785-788, 1989

332. Moriniere P, Marie A, el Esper N, Fardellone P, Deramond H, Remond A, Sebert JL, Fournier A: Destructive spondyloarthropathy with beta 2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis. Nephron 59:654-657, 1991

333. Karlsson FA, Groth T, Sege K, Wibell L, Peterson PA: Turnover in humans of beta 2-microglobulin: The constant chain of HLA-antigens. Eur J Clin Invest 10:293-300, 1980

334. Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H, Mimura N: Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41:1646-1652, 1992

335. Slavotinek JP, Coates PT, McDonald SP, Disney AP, Sage MR: Shoulder appearances at MR imaging in long-term dialysis recipients. Radiology 217:539-543, 2000

336. Floege J, Burchert W, Brandis A, Gielow P, Nonnast-Daniel B, Spindler E, Hundeshagen H, Shaldon S, Koch KM: Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131I-beta 2-microglobulin. Kidney Int 38:1169-1176, 1990

337. Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF Jr: Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 35:926-932, 1992

338. McMahon LP, Radford J, Dawborn JK: Shoulder ultrasound in dialysis related amyloidosis. Clin Nephrol 35:227-232, 1991

339. Schaffer J, Burchert W, Floege J, Gielow P, Kionka C, Linke RP, Weiss EH, Shaldon S, Koch KM: Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients. Kidney Int 58:873-880, 2000

340. Yen TC, Tzen KY, Chen KS, Tsai CJ: The value of gallium-67 and thallium-201 whole-body and single-photon emission tomography images in dialysis-related beta 2-microglobulin amyloid. Eur J Nucl Med 27:56-61, 2000

341. Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, Pugh CW, Winearls CG, Oliver DO, Pepys MB: Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet 338:335-339, 1991

342. Sethi D, Gower PE: Dialysis arthropathy, beta 2-microglobulin and the effect of dialyser membrane. Nephrol Dial Transplant 3:768-772, 1988

343. Sommer R, Valen GJ, Ori Y, Weinstein T, Katz M, Hendel D, Korzets A: Sonographic features of dialysis-related amyloidosis of the shoulder. J Ultrasound Med 19:765-770, 2000

344. Jadoul M, Malghem J, Vande Berg B, van Ypersele de Strihou C: Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: A cross-sectional and longitudinal study. Nephrol Dial Transplant 8:1104-1109, 1993

345. Jadoul M, Garbar C, Noel H, Sennesael J, Vanholder R, Bernaert P, Rorive G, Hanique G, van Ypersele de Strihou C: Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 51:1928-1932, 1997

346. Kuchle C, Fricke H, Held E, Schiffl H: High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 16:484-488, 1996

347. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF 3rd: The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 7:472-478, 1996

348. Risler T, Braun N, Hanel KD, Kuhlmann U, Skroch D, Muller GA: Do different dialysis-membranes affect beta 2-microglobulin kinetics during chronic hemodialysis? Int J Artif Organs 17:581-584, 1994

349. Tielemans C, Dratwa M, Bergmann P, Goldman M, Flamion B, Collart F, Wens R: Continuous ambulatory peritoneal dialysis vs haemodialysis: A lesser risk of amyloidosis? Nephrol Dial Transplant 3:291-294, 1988

350. Hosokawa S, Yoshida O: Removal of silicon, aluminum and beta 2-microglobulin in chronic haemodialysis patients. Int Urol Nephrol 23:281-284, 1991

351. Wiecek A, Kokot F, Kochanska-Dziurowicz A, Grzeszczak W, Zukowska-Szczechowska E: Serum beta 2-microglobulin levels in kidney transplant patients. Transplant Proc 21:2050-2051, 1989

352. Brunner FP, Brynger H, Ehrich JH, Fassbinder W, Geerlings W, Rizzoni G, Selwood NH, Tufveson G, Wing AJ: Case control study on dialysis arthropathy: the influence of two different dialysis membranes: Data from the EDTA Registry. Nephrol Dial Transplant 5:432-436, 1990

353. Blumberg A, Burgi W: Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 27:245-249, 1987

354. Lysaght MJ, Pollock CA, Moran JE, Ibels LS, Farrell PC: Beta-2 microglobulin removal during continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 9:29-35, 1989

355. Scalamogna A, Imbasciati E, De Vecchi A, Castelnovo C, Pagliari B, De Cristofaro V, Ponticelli C: Beta-2 microglobulin in patients on peritoneal dialysis and hemodialysis. Perit Dial Int 9:37-40, 1989

356. Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A: Dialysis-associated arthropathy: A multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 31:157-162, 1992

357. Zingraff J, Beyne P, Urena P, Uzan M, Nguyen Khoa M, Descamps-Latscha B, Drueke T: Influence of haemodialysis membranes on beta 2-microglobulin kinetics: In vivo and in vitro studies. Nephrol Dial Transplant 3:284-290, 1988

358. Mayer G, Thum J, Woloszczuk W, Graf H: Beta-2-microglobulin in hemodialysis patients. Effects of different dialyzers and different dialysis procedures. Am J Nephrol 8:280-284, 1988

359. DiRaimondo CR, Pollak VE: Beta 2-microglobulin kinetics in maintenance hemodialysis: A comparison of conventional and high-flux dialyzers and the effects of dialyzer reuse. Am J Kidney Dis 13:390-395, 1989

360. Ward RA, Buscaroli A, Schmidt B, Stefoni S, Gurland HJ, Klinkmann H: A comparison of dialysers with low-flux membranes: Significant differences in spite of many similarities. Nephrol Dial Transplant 12:965-972, 1997

361. Ward RA, Schaefer RM, Falkenhagen D, Joshua MS, Heidland A, Klinkmann H, Gurland HJ: Biocompatibility of a new high-permeability modified cellulose membrane for haemodialysis. Nephrol Dial Transplant 8:47-53, 1993

362. Klinkmann H, Buscaroli A, Stefoni S: Beta2-microglobulin and low-flux synthetic dialyzers. Artif Organs 22:585-590, 1998

363. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J: Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 39:1012-1019, 1991

364. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52:1096-1101, 1997

365. Schiffl H, Fischer R, Lang SM, Mangel E: Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux. Nephrol Dial Transplant 15:840-845, 2000

366. Mioli VA, Balestra E, Bibiano L, Dellabella S, Fanciulli E, Gaffi G, Perilli A, Petroselli F, Ricciatti AM, Carletti P: Behavior of beta 2-microglobulin (B2-m) serum levels in uremic patients. Int J Artif Organs 17:576-580, 1994

367. Gonzalez T, Cruz A, Balsa A, Jimenez C, Selgas R, Miguel JL, Gijon J: Erosive azotemic osteoarthropathy of the hands in chronic ambulatory peritoneal dialysis and hemodialysis. Clin Exp Rheumatol 15:367-371, 1997

368. Zingraff J, Noel LH, Bardin T, Kuntz D, Dubost C, Drueke T: Beta 2-microglobulin amyloidosis: A sternoclavicular joint biopsy study in hemodialysis patients. Clin Nephrol 33:94-97, 1990

369. Kamphuis AG, Geerlings W, Hazenberg BP, Thijn CJ: Annual evaluation of hip joints and hands for radiographic signs of A beta 2M-amyloidosis in long-term hemodialysis patients. Skeletal Radiol 23:421-427, 1994

370. Stein G, Schneider A, Thoss K, Ritz E, Linke RP, Schaefer K, Sperschneider H, Abendroth K, Funfstuck R: Beta-2-microglobulin-derived amyloidosis: Onset, distribution and clinical features in 13 hemodialysed patients. Nephron 60:274-280, 1992

371. Honda K, Hara M, Ogura Y, Nihei H, Mimura N: Beta 2-microglobulin amyloidosis in hemodialysis patients. An autopsy study of intervertebral disks and posterior longitudinal ligaments. Acta Pathol Jpn 40:820-826, 1990

372. Hurst NP, van den Berg R, Disney A, Alcock M, Albertyn L, Green M, Pascoe V: ‘Dialysis related arthropathy’: A survey of 95 patients receiving chronic haemodialysis with special reference to beta 2 microglobulin related amyloidosis. Ann Rheum Dis 48:409-420, 1989

373. Bouteiller G, Ton That H, Goudable C, Goffinet F, Heche JP, Orfila C, Suc JM: Amyloidosis in chronic hemodialysis: Rheumatological aspects. Contrib Nephrol 62:67-74, 1988

374. Chattopadhyay C, Ackrill P, Clague RB: The shoulder pain syndrome and soft-tissue abnormalities in patients on long-term haemodialysis. Br J Rheumatol 26:181-187, 1987

375. Goldstein S, Winston E, Chung TJ, Chopra S, Pariser K: Chronic arthropathy in long-term hemodialysis. Am J Med 78:82-86, 1985

376. Gejyo F, Homma N, Maruyama H, Arakawa M: Beta 2-microglobulin-related amyloidosis in patients receiving chronic hemodialysis. Contrib Nephrol 68:263-269, 1988

377. Laurent G, Calemard E, Charra B: Dialysis related amyloidosis. Kidney Int suppl 24:S32-S34, 1988

378. Schwarz A, Keller F, Seyfert S, Poll W, Molzahn M, Distler A: Carpal tunnel syndrome: A major complication in long-term hemodialysis patients. Clin Nephrol 22:133-137, 1984

379. Onishi S, Andress DL, Maloney NA, Coburn JW, Sherrard DJ: Beta 2-microglobulin deposition in bone in chronic renal failure. Kidney Int 39:990-995, 1991

380. Kachel HG, Altmeyer P, Baldamus CA, Koch KM: Deposition of an amyloid-like substance as a possible complication of regular dialysis treatment. Contrib Nephrol 36:127-132, 1983

381. Campistol JM, Ponz E, Munoz-Gomez J, Oppenheimer F, Ricard MJ, Vilardell J, Andreu J: Renal transplantation for dialysis amyloidosis. Transplant Proc 24:118-119, 1992

382. Deicher R, Exner M, Cohen G, Haag-Weber M, Horl WH: Neutrophil beta(2)-microglobulin and lactoferrin content in renal failure patients. Am J Kidney Dis 35:1117-1126, 2000

383. Mourad G, Argiles A: Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 7:798-804, 1996

384. Bardin T: Low-dose prednisone in dialysis-related amyloid arthropathy. Rev Rhem Engl Ed 61:S97-S100, 1994

385. Chylkova V, Fixa P, Rozprimova L, Palicka V, Hartmann M, Erben J, Prochazkova J: Beta-2-microglobulin in patients with renal disease. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 31:73-84, 1988

386. Vincent C, Revillard JP: Serum levels and urinary excretion of beta 2 microglobulin in patients under haemodialysis or after renal transplantation. Acta Clin Belg 35:31-39, 1980 (suppl 10)

387. Shiota E, Matsumoto Y, Nakamoto M: Open surgical treatment for dialysis-related arthropathy in the shoulder.J Shoulder Elbow Surg 9:89-92, 2000

388. Nakazawa R, Azuma N, Suzuki M, Nakatani M, Nankou T, Furuyoshi S, Yasuda A, Takata S, Tani N, Kobayashi F: A new treatment for dialysis-related amyloidosis with beta 2-microglobulin adsorbent column. Int J Artif Organs 16:823-829, 1993

389. Akizawa T, Kinugasa E, Kitaoka T, Koshikawa S, Nakabayashi N, Watanabe H, Yamawaki N, Kuroda Y: Removal of beta-2-microglobulin by direct hemoperfusion with a newly developed adsorbent. ASAIO Trans 33:532-537, 1987

390. Milliner DS, Shinaberger JH, Shuman P, Coburn JW: Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions. N Engl J Med 312:165-167, 1985

391. Daly AL, Velazquez LA, Bradley SF, Kauffman CA: Mucormycosis: Association with deferoxamine therapy. Am J Med 87:468-471, 1989

392. Alfrey AC: The toxicity of the aluminum burden. Semin Nephrol 3:329-334, 1983

393. Graf H, Stummvoll HK, Meisinger V, Kovarik J, Wolf A, Pinggera WF: Aluminum removal by hemodialysis. Kidney Int 19:587-592, 1981

394. Trapp GA: Plasma aluminum is bound to transferrin. Life Sci 33:311-316, 1983

395. Alfrey AC: Aluminum metabolism in uremia. Neurotoxicol 1:43-53, 1980

396. Alfrey AC, Hegg A, Craswell P: Metabolism and toxicity of aluminum in renal failure. Am J Clin Nutr 33:1509-1516, 1980

397. Alfrey AC, LeGendre GR, Kaehny WD: The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294:184-188, 1976

398. Kerr DN, Ward MK, Arze RS, Ramos JM, Grekas D, Parkinson IS, Ellis HA, Owen JP, Simpson W, Dewar J, et al: Aluminum-induced dialysis osteodystrophy: the demise of "Newcastle bone disease"? Kidney Int Suppl 18:S58-S64, 1986

399. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN: Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium. Lancet 1:841-845, 1978

400. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN: Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1:406-409, 1979

401. Parkinson IS, Ward MK, Kerr DN: Dialysis encephalopathy, bone disease and anaemia: The aluminum intoxication syndrome during regular haemodialysis. J Clin Pathol 34:1285-1294, 1981

402. McGonigle RJ, Parsons V: Aluminium-induced anaemia in haemodialysis patients. Nephron 39:1-9, 1985

403. O’Hare JA, Murnaghan DJ: Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. N Engl J Med 306:654-656, 1982

404. Berkseth RO, Shapiro FL: An epidemic of dialysis encephalopathy and exposure to high aluminum dialysate, in Schreiner GE, Winchester JF (eds): Controversies in Nephrology. Washington, DC, Georgetown University Press, 1980, pp 42-51

405. Simoes J, Barata JD, D’Haese PC, De Broe ME: Cela n’arrive qu’aux autres (aluminium intoxication only happens in the other nephrologist’s dialysis centre). Nephrol Dial Transplant 9:67-68, 1994

406. LeGendre GR, Alfrey AC: Measuring picogram amounts of aluminum in biological tissue by flameless atomic absorption analysis of a chelate. Clin Chem 22:53-56, 1976

407. Bakir AA, Hryhorczuk DO, Berman E, Dunea G: Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. ASAIO Trans 32:171-176, 1986

408. Kirschbaum BB, Schoolwerth AC: Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci 297:9-11, 1989

409. Molitoris BA, Froment DH, Mackenzie TA, Huffer WH, Alfrey AC: Citrate: A major factor in the toxicity of orally administered aluminum compounds. Kidney Int 36:949-953, 1989

410. Nolan CR, Califano JR, Butzin CA: Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 38:937-941, 1990

411. Sherrard DJ, Walker JV, Boykin JL: Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis 12:126-130, 1988

412. McCauley J, Sorkin MI: Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 4:110-114, 1989

413. Alfrey AC, Mishell JM, Burks J, Contiguglia SR, Rudolph H, Lewin E, Holmes JH: Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 18:257-261266-257, 1972

414. Dunea G, Mahurkar SD, Mamdani B, Smith EC: Role of aluminum in dialysis dementia. Ann Intern Med 88:502-504, 1978

415. Hodsman AB, Sherrard DJ, Wong EG, Brickman AS, Lee DB, Alfrey AC, Singer FR, Norman AW, Coburn JW: Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Ann Intern Med 94:629-637, 1981

416. Hodsman AB, Sherrard DJ, Alfrey AC, Ott S, Brickman AS, Miller NL, Maloney NA, Coburn JW: Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab 54:539-546, 1982

417. Kaehny WD, Hegg AP, Alfrey AC: Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 296:1389-1390, 1977

418. Monier-Faugere MC, Malluche HH: Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 11:111-120, 1996 (suppl 3)

419. Puschett JB, Piraino B, Greenberg A, Rault R: Hypercalcemia in a dialysis patient. Am J Nephrol 6:388-395, 1986

420. Norris KC, Crooks PW, Nebeker HG, Hercz G, Milliner DS, Gerszi K, Slatopolsky E, Andress DL, Sherrard DJ, Coburn JW: Clinical and laboratory features of aluminum-related bone disease: Differences between sporadic and "epidemic" forms of the syndrome. Am J Kidney Dis 6:342-347, 1985

421. Sherrard DJ, Ott SM, Andress DL: Pseudohyperparathyroidism. Syndrome associated with aluminum intoxication in patients with renal failure. Am J Med 79:127-130, 1985

422. Andress DL, Ott SM, Maloney NA, Sherrard DJ: Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312:468-473, 1985

423. Recker R, Schoenfeld P, Letteri J, Slatopolsky E, Goldsmith R, Brickman A: The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med 138 Spec No:857-863, 1978

424. Kausz AT, Antonsen JE, Hercz G, Pei Y, Weiss NS, Emerson S, Sherrard DJ: Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 34:688-693, 1999

425. Milliner DS, Nebeker HG, Ott SM, Andress DL, Sherrard DJ, Alfrey AC, Slatopolsky EA, Coburn JW: Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 101:775-779, 1984

426. Nebeker HG, Andress DL, Milliner DS, Ott SM, Alfrey AC, Slatopolsky EA, Sherrard DJ, Coburn JW: Indirect methods for the diagnosis of aluminum bone disease: Plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Kidney Int Suppl 18:S96-S99, 1986

427. Malluche HH, Smith AJ, Abreo K, Faugere MC: The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 311:140-144, 1984

428. Fournier A, Fohrer P, Leflon P, Moriniere P, Tolani M, Lambrey G, Demontis R, Sebert JL, Van Devyver F, Debroe M: The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalacia. Proc Eur Dial Transplant Assoc Eur Ren Assoc 21:371-376, 1985

429. Andress DL, Maloney NA, Coburn JW, Endres DB, Sherrard DJ: Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. J Clin Endocrinol Metab 65:11-16, 1987

430. Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, Coburn JW, Sherrard DJ: Bone histologic response to deferoxamine in aluminum-related bone disease. Kidney Int 31:1344-1350, 1987

431. Pei Y, Hercz G, Greenwood C, Sherrard D, Segre G, Manuel A, Saiphoo C, Fenton S: Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int 41:1374-1382, 1992

432. Alfrey AC: Aluminum metabolism. Kidney Int suppl 18:S8-S11, 1986

433. Bene C, Manzler A, Bene D, Kranias G: Irreversible ocular toxicity from single "challenge" dose of deferoxamine. Clin Nephrol 31:45-48, 1989

434. Pengloan J, Dantal J, Rossazza C, Abazza M, Nivet H: Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients. Nephron 46:211-212, 1987

435. Boelaert JR, Fenves AZ, Coburn JW: Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry. Am J Kidney Dis 18:660-667, 1991

436. D’Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, Fagalde A, Barsoum RS, Lamberts LV, De Broe ME: Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 10:1874-1884, 1995

437. Canteros A, Diaz-Corte C, Fernandez-Martin JL, Gago E, Fernandez-Merayo C, Cannata J: Ultrafiltrable aluminium after very low doses of desferrioxamine. Nephrol Dial Transplant 13:1538-1542, 1998

438. Jorge C, Gil C, Possante M, Catarino MC, Cruz A, Andrade R, Teixeira R, Santos N, Ferreira A: Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients. Clin Nephrol 52:335-336, 1999

439. Salusky IB, Coburn JW, Paunier L, Sherrard DJ, Fine RN: Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. J Pediatr 105:717-720, 1984

440. Rozas VV, Port FK, Rutt WM: Progressive dialysis encephalopathy from dialysate aluminum. Arch Intern Med 138:1375-1377, 1978

441. Burwen DR, Olsen SM, Bland LA, Arduino MJ, Reid MH, Jarvis WR: Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. Kidney Int 48:469-474, 1995

442. Salusky IB, Foley J, Nelson P, Goodman WG: Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527-531, 1991

443. Sedman AB, Miller NL, Warady BA, Lum GM, Alfrey AC: Aluminum loading in children with chronic renal failure. Kidney Int 26:201-204, 1984

444. D’Haese PC, Clement JP, Elseviers MM, Lamberts LV, Van de Vyver FL, Visser WJ, De Broe ME: Value of serum aluminium monitoring in dialysis patients: A multicentre study. Nephrol Dial Transplant 5:45-53, 1990

445. Heaf JG, Podenphant J, Andersen JR: Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: Role of aluminium hydroxide consumption. Nephron 42:210-216, 1986

446. Channon SM, Arfeen S, Ward MK: Long-term accumulation of aluminum in patients with renal failure. Trace Elements Med 5:147-157, 1988

447. Costantini S, Giordano R, Vernillo I, Piccioni A, Zapponi GA: Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients. Ann Ist Super Sanita 25:457-461, 1989

448. Cases A, Kelly J, Sabater J, Campistol JM, Torras A, Montoliu J, Lopez I, Revert L: Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol 29:176-178, 1988

449. Janssen MJ, van Boven WP: Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Pharm World Sci 18:187-191, 1996

450. Ott SM, Andress DL, Nebeker HG, Milliner DS, Maloney NA, Coburn JW, Sherrard DJ: Changes in bone histology after treatment with desferrioxamine. Kidney Int Suppl 18:S108-S113, 1986

451. Faugere MC, Arnala IO, Ritz E, Malluche HH: Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med 107:481-487, 1986

452. Charhon SA, Chavassieux P, Boivin G, Parisien M, Chapuy MC, Traeger J, Meunier PJ: Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study. Clin Sci (Lond) 73:227-234, 1987

453. Bia MJ, Cooper K, Schnall S, Duffy T, Hendler E, Malluche H, Solomon L: Aluminum induced anemia: Pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 36:852-858, 1989

454. Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llach F: Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 35:1371-1378, 1989

455. McCarthy JT, Milliner DS, Johnson WJ: Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med 74:257-276, 1990

456. Ackrill P, Ralston AJ, Day JP, Hodge KC: Successful removal of aluminium from patient with dialysis encephalopathy. Lancet 2:692-693, 1980

457. Hood SA, Clark WF, Hodsman AB, Bolton CF, Cordy PE, Anderson C, Leung F: Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol. Am J Nephrol 4:369-374, 1984

458. Milne FJ, Sharf B, Bell P, Meyers AM: The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Clin Nephrol 20:202-207, 1983

459. Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM: Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med 146:2063-2064, 1986

460. Ackrill P, Ralston AJ, Day JP: Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney Int Suppl 18:S104-S107, 1986

461. Altmann P, Plowman D, Marsh F, Cunningham J: Aluminium chelation therapy in dialysis patients: Evidence for inhibition of haemoglobin synthesis by low levels of aluminium. Lancet 1:1012-1015, 1988

462. von Bonsdorff M, Sipila R, Pitkanen E: Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload. Scand J Urol Nephrol suppl 131:49-54, 1990

463. Van Cutsem J, Boelaert JR: Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 36:1061-1068, 1989

464. Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, Van Landuyt HW, Schneider YJ: Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 91:1979-1986, 1993

465. Boelaert JR, Vergauwe PL, Vandepitte JM: Mucormycosis infection in dialysis patients. Ann Intern Med 107:782-783, 1987

466. De Broe ME, Drueke TB, Ritz E: Consensus Conference: Diagnosis and treatment of aluminum overload in end-stage renal failure patients. Nephrol Dial Transplant 8:1-4, 1993 (suppl 1)

467. Hercz G, Andress DL, Nebeker HG, Shinaberger JH, Sherrard DJ, Coburn JW: Reversal of aluminum-related bone disease after substituting calcium carbonate for aluminum hydroxide. Am J Kidney Dis 11:70-75, 1988

468. Hercz G, Andress DL, Norris KC, Shinaberger JH, Slatopolsky EA, Sherrard DJ, Coburn JW: Improved bone formation in dialysis patients after substitution of calcium carbonate for aluminum gels. Trans Assoc Am Physicians 100:139-146, 1987

469. Adhemar JP, Laederich J, Jaudon MC, Masselot JP, Galli A, Kleinknecht D: Removal of aluminium from patients with dialysis encephalopathy. Lancet 2:1311, 1980

470. Arze RS, Parkinson IS, Cartlidge NE, Britton P, Ward MK: Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment. Lancet 2:1116, 1981

471. Pogglitsch H, Petek W, Wawschinek O, Holzer W: Treatment of early stages of dialysis encephalopathy by aluminium depletion. Lancet 2:1344-1345, 1981

472. Molitoris BA, Alfrey AC, Alfrey PS, Miller NL: Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 34:98-101, 1988

473. Delmez J, Weerts C, Lewis-Finch J, Windus D, Slatopolsky E: Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients. Am J Kidney Dis 13:308-311, 1989

474. Vasilakakis DM, D’Haese PC, Lamberts LV, Lemoniatou E, Digenis PN, De Broe ME: Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis. Kidney Int 41:1400-1407, 1992

475. Hercz G, Salusky IB, Norris KC, Fine RN, Coburn JW: Aluminum removal by peritoneal dialysis: Intravenous vs. intraperitoneal deferoxamine. Kidney Int 30:944-948, 1986

476. Molitoris BA, Alfrey PS, Miller NL, Hasbargen JA, Kaehney WD, Alfrey AC, Smith BJ: Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation. Kidney Int 31:986-991, 1987

477. Barata JD, D’Haese PC, Pires C, Lamberts LV, Simoes J, De Broe ME: Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 11:125-132, 1996

478. Widmer B, Gerhardt RE, Harrington JT, Cohen JJ: Serum electrolyte and acid base composition. The influence of graded degrees of chronic renal failure. Arch Intern Med 139:1099-1102, 1979

479. Eiser AR, Slifkin RF, Neff MS: Intestinal mucormycosis in hemodialysis patients following deferoxamine. Am J Kidney Dis 10:71-73, 1987

480. Veis JH, Contiguglia R, Klein M, Mishell J, Alfrey AC, Shapiro JI: Mucormycosis in deferoxamine-treated patients on dialysis. Ann Intern Med 107:258, 1987

481. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR: Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 45:667-671, 1994

482. Coburn JW, Maung HM: Mucormycosis in dialysis patients, in Sweny P, Rubin RH, Tolkoff-Rubin N (eds): London, UK, Oxford University Press, 2002

483. Chou FF, Chan HM, Huang TJ, Lee CH, Hsu KT: Autotransplantation of parathyroid glands into subcutaneous forearm tissue for renal hyperparathyroidism. Surgery 124:1-5, 1998

484. Kostakis A, Vaiopoulos G, Kostantopoulos K, Zavos G, Bocos I, Sgouromalis S: Parathyroidectomy in the treatment of secondary hyperparathyroidism in chronic renal failure. Int Surg 82:85-86, 1997

485. Gasparri G, Camandona M, Jeantet A, Nano M, Desimone M, Bronda M, Deipoli M: Results after 223 parathyroidectomies for secondary hyperparathyroidism. Acta Chir Austriaca 28:32-34, 1996 (suppl 124)

486. Neonakis E, Wheeler MH, Krishnan H, Coles GA, Davies F, Woodhead JS: Results of surgical treatment of renal hyperparathyroidism. Arch Surg 130:643-648, 1995

487. Gagne ER, Urena P, Leite-Silva S, Zingraff J, Chevalier A, Sarfati E, Dubost C, Drueke TB: Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 3:1008-1017, 1992

488. Takagi H, Tominaga Y, Uchida K, Yamada N, Kawai M, Kano T, Morimoto T: Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 200:18-23, 1984

489. Esselstyn CB Jr, Popowniak KL: Parathyroid surgery in the treatment of renal osteodystrophy and tertiary hyperparathyroidism. Surg Clin North Am 51:1211-1217, 1971

490. Olaizola I, Zingraff J, Heuguerot C, Fajardo L, Leger A, Lopez J, Acuna G, Petraglia A, Alvarez A, Caorsi H, Drueke T, Ambrosoni P: [(99m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: Static and dynamic explorations. Nephrol Dial Transplant 15:1201-1206, 2000

491. Neumann DR, Esselstyn CB Jr, Madera A, Wong CO, Lieber M: Parathyroid detection in secondary hyperparathyroidism with 123I/99mTc-sestamibi subtraction single photon emission computed tomography. J Clin Endocrinol Metab 83:3867-3871, 1998

492. Blocklet D, Martin P, Schoutens A, Verhas M, Hooghe L, Kinnaert P: Presurgical localization of abnormal parathyroid glands using a single injection of technetium-99m methoxyisobutylisonitrile: comparison of different techniques including factor analysis of dynamic structures. Eur J Nucl Med 24:46-51, 1997

493. Tanaka Y, Tominaga Y, Funahashi H, Sato K, Numano M, Takagi H: Preoperative localization studies in secondary hyperplasia. Acta Chir Austriaca 28:14-16, 1996 (suppl 124)

494. Hindie E, Urena P, Jeanguillaume C, Melliere D, Berthelot JM, Menoyo-Calonge V, Chiappini-Briffa D, Janin A, Galle P: Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet 353:2200-2204, 1999

495. Ishibashi M, Nishida H, Okuda S, Suekane S, Hayabuchi N: Localization of parathyroid glands in hemodialysis patients using Tc-99m sestamibi imaging. Nephron 78:48-53, 1998

496. Jeanguillaume C, Urena P, Hindie E, Prieur P, Petrover M, Menoyo-Calonge V, Janin A, Chiappini-Briffa D, Melliere D, Boulahdour H, Galle P: Secondary hyperparathyroidism: Detection with I-123-Tc-99m-Sestamibi subtraction scintigraphy versus US. Radiology 207:207-213, 1998

497. Chesser AM, Carroll MC, Lightowler C, Macdougall IC, Britton KE, Baker LR: Technetium-99m methoxy isobutyl isonitrile (MIBI) imaging of the parathyroid glands in patients with renal failure. Nephrol Dial Transplant 12:97-100, 1997

498. Pons F, Torregrosa JV, Vidal-Sicart S, Sabater L, Fuster D, Fernandez-Cruz L, Herranz R: Preoperative parathyroid gland localization with technetium-99m sestamibi in secondary hyperparathyroidism. Eur J Nucl Med 24:1494-1498, 1997

499. Takebayashi S, Matsui K, Onohara Y, Hidai H: Sonography for early diagnosis of enlarged parathyroid glands in patients with secondary hyperparathyroidism. AJR Am J Roentgenol 148:911-914, 1987

500. Fabretti F, Calabrese V, Fornasari V, Poletti I: Subtotal parathyroidectomy for secondary hyperparathyroidism in chronic renal failure. J Laryngol Otol 105:562-567, 1991

501. Tomic Brzac H, Pavlovic D, Halbauer M, Pasini J: Parathyroid sonography in secondary hyperparathyroidism: Correlation with clinical findings. Nephrol Dial Transplant 4:45-50, 1989

502. Takagi H, Tominaga Y, Uchida K, Yamada N, Ishii T, Morimoto T, Yasue M: Preoperative diagnosis of secondary hyperparathyroidism using computed tomography. J Comput Assist Tomogr 6:527-528, 1982

503. Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kurokawa K: Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients—The Japanese strategy. Japanese Working Group on PEIT of Parathyroid, Tokyo, Japan. Nephrol Dial Transplant 14:2574-2577, 1999

504. Messa P, Mioni G, Maio GD, Ferrando C, Lamperi D, Famularo A, Paoletti E, Cannella G: Derangement of acid-base balance in uremia and under hemodialysis. J Nephrol 14:S12-21, 2001 (suppl 4)

505. Wallia R, Greenberg A, Piraino B, Mitro R, Puschett JB: Serum electrolyte patterns in end-stage renal disease. Am J Kidney Dis 8:98-104, 1986

506. Lemann J Jr, Lennon EJ, Goodman AD, Litzow JR, Relman AS: The net balance of acid of fixed acid in subjects given large loads of acid or alkali. J Clin Invest 44:507-517, 1965

507. Lemann J Jr, Litzow JR, Lennon EJ: The effects of chronic acid loads in normal man: Further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. J Clin Invest 45:1608-1614, 1966

508. Goodman AD, Lemann JJ, Lennon EJ, Relman AS: Production, excretion and net balance of fixed acid in patients with renal acidosis.J Clin Invest 45:495-506, 1965

509. Litzow JR, Lemann J Jr, Lennon EJ: The effect of treatment of acidosis on calcium balance in patients with chronic azotemic renal disease. J Clin Invest 46:280-286, 1967

510. Bushinsky DA, Chabala JM, Gavrilov KL, Levi-Setti R: Effects of in vivo metabolic acidosis on midcortical bone ion composition. Am J Physiol 277:F813-819, 1999

511. Frick KK, Bushinsky DA: In vitro metabolic and respiratory acidosis selectively inhibit osteoblastic matrix gene expression. Am J Physiol 277:F750-F755, 1999

512. Nordstrom T, Shrode LD, Rotstein OD, Romanek R, Goto T, Heersche JN, Manolson MF, Brisseau GF, Grinstein S: Chronic extracellular acidosis induces plasmalemmal vacuolar type H+ ATPase activity in osteoclasts. J Biol Chem 272:6354-6360, 1997

513. Green J, Maor G: Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers. Kidney Int 57:2258-2267, 2000

514. Langman CB, Bushinsky DA, Favus MJ, Coe FL: Ca and P regulation of 1,25(OH)2D3 synthesis by vitamin D-replete rat tubules during acidosis. Am J Physiol 251:F911-F918, 1986

515. Alpern RJ, Sakhaee K: The clinical spectrum of chronic metabolic acidosis: Homeostatic mechanisms produce significant morbidity. Am J Kidney Dis 29:291-302, 1997

516. Hory B, Drueke TB: The parathyroid-bone axis in uremia: New insights into old questions. Curr Opin Nephrol Hypertens 6:40-48, 1997

517. Bailey RR: Chronic acidosis with metabolic bone disease. N Z Med J 98:483-484, 1985

518. Lemann J Jr, Adams ND, Wilz DR, Brenes LG: Acid and mineral balances and bone in familial proximal renal tubular acidosis. Kidney Int 58:1267-1277, 2000

519. Domrongkitchaiporn S, Pongsakul C, Stitchantrakul W, Sirikulchayanonta V, Ongphiphadhanakul B, Radinahamed P, Karnsombut P, Kunkitti N, Ruang-raksa C, Rajatanavin R: Bone mineral density and histology in distal renal tubular acidosis. Kidney Int 59:1086-1093, 2001

520. McSherry E, Morris RC Jr: Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest 61:509-527, 1978

521. Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C: Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36:1112-1118, 1989

522. Coen G, Manni M, Addari O, Ballanti P, Pasquali M, Chicca S, Mazzaferro S, Napoletano I, Sardella D, Bonucci E: Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: Effect of calcitriol treatment. Miner Electrolyte Metab 21:375-382, 1995

523. Clinical practice guidelines for nutrition in chronic renal failure. KDOQI, National Kidney Foundation. Am J Kidney Dis 35:S1-S140, 2000 (suppl)

524. Mauro LS, Kuhl DA, Kirchhoff JR, Mauro VF, Hamilton RW: Impact of oral bases on aluminum absorption. Am J Ther 8:21-25, 2001

525. Bonomini V, Feletti C, Di Felice A, Buscaroli A: Bone remodelling after renal transplantation (RT). Adv Exp Med Biol 178:207-216, 1984

526. Kober M, Schneider H, Reinold HM: Development of renal osteodystrophy after kidney transplantation. Kidney Int 28:378, 1985

527. Nielsen HE, Melsen F, Christensen MS: Aseptic necrosis of bone following renal transplantation. Clinical and biochemical aspects and bone morphometry. Acta Med Scand 202:27-32, 1977

528. National Institutes of Health. Conference on Osteoporosis Prevention, Diagnosis, and Therapy, 2000

529. Massari PU: Disorders of bone and mineral metabolism after renal transplantation. Kidney Int 52:1412-1421, 1997

530. Rosenbaum RW, Hruska KA, Korkor A, Anderson C, Slatopolsky E: Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 19:568-578, 1981

531. Moorhead JF, Wills MR, Ahmed KY, Baillod RA, Varghese Z, Tatler GL: Hypophosphataemic osteomalacia after cadaveric renal transplantation. Lancet 1:694-697, 1974

532. Ambuhl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U: Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: Impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 34:875-883, 1999

533. Better OS: Tubular dysfunction following kidney transplantation. Nephron 25:209-213, 1980

534. Ward HN, Pabico RC, McKenna BA, Freeman RB: The renal handling of phosphate by renal transplant patients: correlation with serum parathyroid hormone (SPTH), cyclic 3`,5`-adenosine monophosphate (cAMP) urinary excretion, and allograft function. Adv Exp Med Biol 81:173-181, 1977

535. Graf H, Kovarik J, Stummvoll HK, Wolf A, Pinggera WF: Handling of phosphate by the transplanted kidney. Proc Eur Dial Transplant Assoc 16:624-629, 1979

536. Garabedian M, Silve C, Levy D, Bourdeau A, Ulmann A, Broyer M, Balsan S: Chronic hypophosphatemia in kidney transplanted children and young adults. Adv Exp Med Biol 128:249-254, 1980

537. Olgaard K, Madsen S, Lund B, Sorensen OH: Pathogenesis of hypophosphatemia in kidney necrograft recipients: A controlled trial. Adv Exp Med Biol 128:255-261, 1980

538. Sakhaee K, Brinker K, Helderman JH, Bengfort JL, Nicar MJ, Hull AR, Pak CY: Disturbances in mineral metabolism after successful renal transplantation. Miner Electrolyte Metab 11:167-172, 1985

539. Parfitt AM, Kleerekoper M, Cruz C: Reduced phosphate reabsorption unrelated to parathyroid hormone after renal transplantation: Implications for the pathogenesis of hyperparathyroidism in chronic renal failure. Miner Electrolyte Metab 12:356-362, 1986

540. Steiner RW, Ziegler M, Halasz NA, Catherwood BD, Manolagas S, Deftos LJ: Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 56:843-846, 1993

541. Uchida K, Tominaga Y, Tanaka Y, Takagi H: Renal transplantation and secondary hyperparathyroidism. Semin Surg Oncol 13:97-103, 1997

542. Saha HH, Salmela KT, Ahonen PJ, Pietila KO, Morsky PJ, Mustonen JT, Lalla ML, Pasternack AI: Sequential changes in vitamin D and calcium metabolism after successful renal transplantation. Scand J Urol Nephrol 28:21-27, 1994

543. Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardellone P, Brazier M, El Esper I, Petit J, Achard JM, Pruna A, Fournier A: Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 58:1788-1796, 2000

544. Green J, Debby H, Lederer E, Levi M, Zajicek HK, Bick T: Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 60:1182-1196, 2001

545. Drezner MK: PHEX gene and hypophosphatemia. Kidney Int 57:9-18, 2000

546. Madsen S, Olgaard K, Lund B, Sorensen OH: Pathogenesis of hypophosphataemia in kidney necrograft recipients: A controlled trial. Proc Eur Dial Transplant Assoc 16:618-623, 1979

547. Christensen MS, Nielsen HE: Parathyroid function after renal transplantation: Interrelationships between renal function, serum calcium and serum parathyroid hormone in normocalcemic long-term survivors. Clin Nephrol 8:472-476, 1977

548. Chatterjee SN, Massry SG, Friedler RM, Singer FR, Berne TV: The high incidence of persistent secondary hyperparathyroidism after renal homotransplantation. Surg Gynecol Obstet 143:440-442, 1976

549. Pletka PG, Strom TB, Hampers CL, Griffiths H, Wilson RE, Bernstein DS, Sherwood LM, Merrill JP: Secondary hyperparathyroidism in human kidney transplant recipients. Nephron 17:371-381, 1976

550. Ulmann A, Chkoff N, Lacour B: Disorders of calcium and phosphorus metabolism after successful kidney transplantation. Adv Nephrol Necker Hosp 12:331-340, 1983

551. Parfitt AM: Hypercalcemic hyperparathyroidism following renal transplantation: Differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 8:92-112, 1982

552. Nielsen HE, Christensen MS, Melsen F, Torring S: Bone disease, hypophosphatemia and hyperparathyroidism after renal transplantation. Adv Exp Med Biol 81:603-610, 1977

553. Higgins RM, Richardson AJ, Endre ZH, Frostick SP, Morris PJ: Hypophosphataemia after renal transplantation: Relationship to immunosuppressive drug therapy and effects on muscle detected by 31P nuclear magnetic resonance spectroscopy. Nephrol Dial Transplant 5:62-68, 1990

554. Farrington K, Varghese Z, Newman SP, Ahmed KY, Fernando ON, Moorhead JF: Dissociation of absorptions of calcium and phosphate after successful cadaveric renal transplantation. Br Med J 1:712-714, 1979

555. Graf H, Kovarik J, Stummvoll HK, Wolf A, Pinggera WF: Renal phosphate wasting after successful kidney transplantation: 1-alpha vitamin D therapy in patients with normal parathyroid gland activity. Nephron 28:285-288, 1981

556. Kumar R: Phosphatonin—A new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrol Dial Transplant 12:11-13, 1997

557. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD: Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544-550, 1991

558. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11:1093-1099, 2000

559. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P: Changes in bone mass early after kidney transplantation. J Bone Miner Res 9:1-9, 1994

560. Almond MK, Kwan JT, Evans K, Cunningham J: Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 66:52-57, 1994

561. Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schollmeyer PJ: Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients. Nephrol Dial Transplant 10:2096-2100, 1995

562. Rubin MF, Narins RG: Hypophosphatemia: Pathophysiological and practical aspects of its therapy. Semin Nephrol 10:536-545, 1990

563. Julian BA, Quarles LD, Niemann KM: Musculoskeletal complications after renal transplantation: Pathogenesis and treatment. Am J Kidney Dis 19:99-120, 1992

564. Newman JH, Neff TA, Ziporin P: Acute respiratory failure associated with hypophosphatemia. N Engl J Med 296:1101-1103, 1977

565. Knochel JP, Caskey JH: The mechanism of hypophosphatemia in acute heat stroke. JAMA 238:425-426, 1977

566. de Francisco AM, Riancho JA, Amado JA, del Arco C, Macias JG, Cotorruelo JG, Arias M: Calcium, hyperparathyroidism, and vitamin D metabolism after kidney transplantation. Transplant Proc 19:3721-3723, 1987

567. Lobo PI, Cortez MS, Stevenson W, Pruett TL: Normocalcemic hyperparathyroidism associated with relatively low 1: 25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 9:277-281, 1995

568. Dumoulin G, Hory B, Nguyen NU, Bresson C, Fournier V, Bouhaddi M, Chalopin JM, Saint-Hillier Y, Regnard J: No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 29:746-753, 1997

569. Nehme D, Rondeau E, Paillard F, Moreau JF, Nussaume O, Kanfer A, Sraer JD: Aseptic necrosis of bone following renal transplantation: Relation with hyperparathyroidism. Nephrol Dial Transplant 4:123-128, 1989

570. Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, Perez L, Machado M, de Bonis E, Losada M, Hernandez D, Lorenzo V: Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 13:94-97, 1998 (suppl 3)

571. Dumoulin G, Hory B, Nguyen NU, Henriet MT, Bresson C, Regnard J, Saint-Hillier Y: Lack of evidence that cyclosporine treatment impairs calcium-phosphorus homeostasis and bone remodeling in normocalcemic long-term renal transplant recipients. Transplantation 59:1690-1694, 1995

572. Traindl O, Langle F, Reading S, Franz M, Watschinger B, Klauser R, Woloszczuk W, Kovarik J: Secondary hyperparathyroidism and acute tubular necrosis following renal transplantation. Nephrol Dial Transplant 8:173-176, 1993

573. Kleerekoper M, Ibels LS, Ingham JP, McCarthy SW, Mahony JF, Stewart JH, Posen S: Hyperparathyroidism after renal transplantation. Br Med J 3:680-682, 1975

574. Cundy T, Kanis JA, Heynen G, Morris PJ, Oliver DO: Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 52:67-78, 1983

575. Uchida H, Andoh Y, Tomikawa S, Nishimura Y, Nagano T, Ichikawa N, Kikuchi K, Nomura Y, Degawa T, Meigata K, et al: Tertiary hyperparathyroidism after renal transplantation—Report of two cases and comparative study of parathyroid function with secondary hyperparathyroidism in chronic renal failure. Transplant Proc 26:2167-2169, 1994

576. Schmid T, Muller P, Spelsberg F: Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant 12:2393-2396, 1997

577. Fernandez E, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J: Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure.J Am Soc Nephrol 8:1546-1552, 1997

578. Torres A, Machado M, Concepcion MT, Martin N, Lorenzo V, Hernandez D, Rodriguez AP, Rodriguez A, de Bonis E, Gonzalez-Posada JM, Hernandez A, Salido E: Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 50:1726-1733, 1996

579. Alsina J, Gonzalez MT, Bonnin R, Ricart Y, Castelao AM, Gonzalez C, Grino JM: Long-term evolution of renal osteodistrophy after renal transplantation. Transplant Proc 21:2151-2158, 1989

580. Riancho JA, de Francisco AL, del Arco C, Amado JA, Cotorruelo JG, Arias M, Gonzalez-Macias J: Serum levels of 1,25-dihydroxyvitamin D after renal transplantation. Miner Electrolyte Metab 14:332-337, 1988

581. Felsenfeld AJ, Gutman RA, Drezner M, Llach F: Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 12:333-341, 1986

582. Alfrey AC, Jenkins D, Groth CG, Schorr WS, Gecelter L, Ogden DA: Resolution of hyperparathyroidism, renal osteodystrophy and metastatic calcification after renal homotransplantation. N Engl J Med 279:1349-1356, 1968

583. Johnson JW, Hattner RS, Hampers CL, Bernstein DS, Merrill JP, Sherwood LM: Secondary hyperparathyroidism in chronic renal failure. Effects of renal homotransplantation. JAMA 215:478-480, 1971

584. Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, Di Loreto PL, Bresadola F, Mioni G: Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 54:1704-1713, 1998

585. Bernheim J, Touraine JL, David L, Faivre JM, Traeger J: Evolution of secondary hyperparathyroidism after renal transplantation. Nephron 16:381-387, 1976

586. Chatterjee SN, Friedler RM, Berne TV, Oldham SB, Singer FR, Massry SG: Persistent hypercalcemia after successful renal transplantation. Nephron 17:1-7, 1976

587. D’Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, Belzer FO, Starling JR: Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 106:1049-1055, discussion 1055-1046, 1989

588. Massry SG, Gordon A, Coburn JW, Kaplan L, Franklin SS, Maxwell MH, Kleeman CR: Vascular calcification and peripheral necrosis in a renal transplant recipient. Reversal of lesions following subtotal parathyroidectomy. Am J Med 49:416-422, 1970

589. McCarron DA, Muther RS, Lenfesty B, Bennett WM: Parathyroid function in persistent hyperparathyroidism: Relationship to gland size. Kidney Int 22:662-670, 1982

590. Pieper R, Alveryd A, Lundgren G, Collste H, Magnusson G, Svahn T, Groth CG:  Secondary hyperparathyroidism and its sequelae in renal transplant recipients. Long term findings in a series of conservatively managed patients. Scand J Urol Nephrol Suppl 144-148, 1977

591. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N: Bone loss after renal transplantation: Role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 14:457-463, 2000

592. Vlcek J, Binswanger U, Keusch G, Zaruba J: Hyperparathyroidism after kidney transplantation: A retrospective case controlled study. Klin Wochenschr 69:669-673, 1991

593. Pietschmann P, Vychytil A, Woloszczuk W, Kovarik J: Bone metabolism in patients with functioning kidney grafts: Increased serum levels of osteocalcin and parathyroid hormone despite normalisation of kidney function. Nephron 59:533-536, 1991

594. Tominaga Y, Uchida K, Sato K, Numano M, Tanaka Y, Takagi H: Parathyroidectomy before and after renal transplantation. Transplant Proc 24:1861-1862, 1992

595. Llach F: Parathyroidectomy in chronic renal failure: Indications, surgical approach and the use of calcitriol. Kidney Int suppl 29:S62-S68, 1990

596. McCarron DA, Lenfesty B, Vetto M, Barry J, Bennett WM: Total parathyroidectomy for posttransplantation hyperparathyroidism. Transplantation 40:266-269, 1985

597. Garvin PJ, Castaneda M, Linderer R, Dickhans M: Management of hypercalcemic hyperparathyroidism after renal transplantation. Arch Surg 120:578-583, 1985

598. Punch JD, Thompson NW, Merion RM: Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients. A 25-year single-center experience. Arch Surg 130:538-542; discussion 542-533, 1995

599. Higgins RM, Richardson AJ, Ratcliffe PJ, Woods CG, Oliver DO, Morris PJ: Total parathyroidectomy alone or with autograft for renal hyperparathyroidism? Q J Med 79:323-332, 1991

600. Velasquez-Forero F, Mondragon A, Herrero B, Pena JC: Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 11:58-64, 1996 (suppl 3)

601. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53:1358-1364, 1998

602. Carlini RG, Rojas E, Arminio A, Weisinger JR, Bellorin-Font E: What are the bone lesions in patients with more than four years of a functioning renal transplant? Nephrol Dial Transplant 13:103-104, 1998 (suppl 3)

603. Briner VA, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V, Malluche HH: Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation 59:1393-1400, 1995

604. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ: Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 59:982-986, 1995

605. Schuster VL, Chesnut CH, 3rd, Baylink DJ, Sherrard DJ: Calcium balance in uremia: Longitudinal study of long-term survivors. Nephron 41:132-140, 1985

606. Sambrook PN, Kelly PJ, Keogh AM, Macdonald P, Spratt P, Freund J, Eisman JA: Bone loss after heart transplantation: A prospective study. J Heart Lung Transplant 13:116-120, discussion 121, 1994

607. Tanaka Y, Deluca HF: The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 154:566-574, 1973

608. Adinoff AD, Hollister JR: Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268, 1983

609. Rickers H, Deding A, Christiansen C, Rodbro P: Mineral loss in cortical and trabecular bone during high-dose prednisone treatment. Calcif Tissue Int 36:269-273, 1984

610. Shioi A, Ross FP, Teitelbaum SL: Enrichment of generated murine osteoclasts. Calcif Tissue Int 55:387-394, 1994

611. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747-1752, 1993

612. Levi M: Post-transplant hypophosphatemia. Kidney Int 59:2377-2387, 2001

613. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, de Bonis E, Darias E, Gonzalez-Posada JM, et al: Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int 47:1434-1442, 1995

614. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ: Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 58:912-915, 1994

615. Heath H 3rd, Hodgson SF, Kennedy MA: Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302:189-193, 1980

616. Torres A, Concepcion MT, Martin N, et al: Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Transplantation 59:1393, 1995

617. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 112:352-364, 1990

618. Dempster DW: Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137-141, 1989

619. Meunier PJ, Briancon D, Chavassieux P: Treatment with fluoride: Bone histomorphometric findings, in Christiansen C, Johansen JS, Riis BJ (eds): Osteoporosis. Amsterdam, The Netherlands, Elsevier, 1996, pp 824-828

620. Dempster DW, Arlot MA, Meunier PJ: Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410-417, 1983

621. Baylink DJ: Glucocorticoid-induced osteoporosis. N Engl J Med 309:306-308, 1983

622. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP: The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72:382-386, 1991

623. Ferraris JR, Pasqualini T, Legal S, Sorroche P, Galich AM, Pennisi P, Domene H, Jasper H: Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol 14:682-688, 2000

624. Caglar M, Adeera L: Factors affecting bone mineral density in renal transplant patients. Ann Nucl Med 13:141-145, 1999

625. Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R: Bone loss in long-term renal transplantation: Histopathology and densitometry analysis. Kidney Int 55:2021-2029, 1999

626. Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C: Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplantation 63:380-386, 1997

627. Stewart PJ, Stern PH: Cyclosporines: Correlation of immunosuppressive activity and inhibition of bone resorption. Calcif Tissue Int 45:222-226, 1989

628. Orcel P, Denne MA, de Vernejoul MC: Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 128:1638-1646, 1991

629. Movsowitz C, Epstein S, Ismail F, Fallon M, Thomas S: Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption. J Bone Miner Res 4:393-398, 1989

630. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S: The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 124:2179-2184, 1989

631. Movsowitz C, Schlosberg M, Epstein S, Ismail F, Fallon M, Thomas S: Combined treatment with cyclosporin A and cortisone acetate minimizes the adverse bone effects of either agent alone. J Orthop Res 8:635-641, 1990

632. Landmann J, Renner N, Gachter A, Thiel G, Harder F: Cyclosporin A and osteonecrosis of the femoral head. J Bone Joint Surg Am 69:1226-1228, 1987

633. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP: Osteoporosis after cardiac transplantation. Am J Med 94:257-264, 1993

634. Ficat RP: Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment.J Bone Joint Surg Br 67:3-9, 1985

635. Felson DT, Anderson JJ: Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1:902-906, 1987

636. Sherrard DJ: Renal osteodystrophy. Semin Nephrol 6:56-67, 1986

637. Ponticelli C, Civati G, Tarantino A, Quarto di Palo F, Corbetta G, Minetti L, Vegeto A, Belli L: Randomized study with cyclosporine in kidney transplantation: 10-year follow-up. J Am Soc Nephrol 7:792-797, 1996

638. De Vecchi A, Rivolta E, Tarantino A, Egidi F, Berardinelli L, Vegeto A, Ponticelli C: Controlled trial of two different methylprednisolone doses in cadaveric renal transplantation. Nephron 41:262-266, 1985

639. Papadakis J, Brown CB, Cameron JS, Adu D, Bewick M, Donaghey R, Ogg CS, Rudge C, Williams DG, Taube D: High versus "low" dose corticosteroids in recipients of cadaveric kidneys: Prospective controlled trial. Br Med J (Clin Res Ed) 286:1097-1100, 1983

640. Morris PJ, Chan L, French ME, Ting A: Low dose oral prednisolone in renal transplantation. Lancet 1:525-527, 1982

641. Lausten GS, Lemser T, Jensen PK, Egfjord M: Necrosis of the femoral head after kidney transplantation. Clin Transplant 12:572-574, 1998

642. Davidson JK, Tsakiris D, Briggs JD, Junor BJ: Osteonecrosis and fractures following renal transplantation. Clin Radiol 36:27-35, 1985

643. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC: Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456-461, 1990

644. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271, 1990

645. Van Cleemput J, Daenen W, Geusens P, Dequeker P, Van De Werf F, VanHaecke J: Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation 61:1495-1499, 1996

646. Hofbauer LC, Heufelder AE [The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis]. Dtsch Med Wochenschr 121:953-957, 1996

647. Reid IR, King AR, Alexander CJ, Ibbertson HK: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:143-146, 1988

648. Fan SL, Almond MK, Ball E, Evans K, Cunningham J: Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int 57:684-690, 2000

649. Shane E, Thys-Jacobs S, Papadopoulos A, et al: Antiresorptive therapy prevents bone loss after cardiac transplantation (CTX). J Bone Miner Res 11:S340, 1996 (abstr)

650. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443, 1995

651. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021, 1996

652. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C: Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268-1274, 1988

653. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH 3rd: Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295-303, 1984

654. Resch H, Pietschmann P, Willvonseder R: Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures. Calcif Tissue Int 45:209-213, 1989

655. Ringe JD, Welzel D: Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33:35-39, 1987

656. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J: Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis 142:104-107, 1990

657. Murrills RJ, Shane E, Lindsay R, Dempster DW: Bone resorption by isolated human osteoclasts in vitro: Effects of calcitonin. J Bone Miner Res 4:259-268, 1989

658. Kurose H, Seino Y, Shima M, Tanaka H, Ishida M, Yamaoka K, Yabuuchi H: Intranasal absorption of salmon calcitonin. Calcif Tissue Int 41:249-251, 1987

659. Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P: 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1483, 1987

660. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS: Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 30:435-442, 1989

661. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ: Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 66:1004-1008, 1998

662. Adams JS, Wahl TO, Lukert BP: Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 30:217-221, 1981

663. Lemann J Jr, Gray RW, Maierhofer WJ, Cheung HS: Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int 28:951-958, 1985

664. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, Cornoni-Huntley J, Ostfeld AM: Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 322:286-290, 1990

2003 National Kidney Foundation, Inc.